Loss of FHIT Expression in Breast Cancer Is Correlated with Poor Prognostic Markers
Open Access
- 1 July 2005
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 14 (7), 1681-1685
- https://doi.org/10.1158/1055-9965.epi-04-0278
Abstract
Objective: The fragile histidine triad (FHIT) gene is a putative tumor suppressor gene that is thought to be involved in the carcinogenesis of breast cancer. Loss of FHIT expression has been observed in up to 72% of breast cancers and has been associated with increased p53, a high proliferation index, and increased tumor size and grade. However, loss of FHIT expression has not been investigated in association with apoptosis and cyclooxygenase-2 (COX-2) expression in breast cancer. Furthermore, expression of FHIT in primary breast tumors and their metastatic axillary lymph nodes has also not been previously described. The purpose of this study was to evaluate the expression of FHIT, COX-2, bcl-2, and p53 in primary breast tumor tissue; correlate their expression with known clinical and pathologic markers; and in cases when tissue was available, evaluate the expression of FHIT and COX-2 in the corresponding metastatic axillary lymph node in the same patient.This publication has 12 references indexed in Scilit:
- Elevated expression of cyclooxygenase‐2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinomaCancer, 2003
- Factors influencing the prognostic role of oestrogen and progesterone receptor levels in breast cancer—results of the analysis of 670 patients with 11 years of follow-upEuropean Journal of Cancer, 2002
- The tumor-suppressor gene FHIT is involved in the regulation of apoptosis and in cell cycle controlProceedings of the National Academy of Sciences of the United States of America, 1999
- THE ROLE OF THE FHIT/FRA3B LOCUS IN CANCERAnnual Review of Genetics, 1998
- Expression of Cyclooxygenase-1 and Cyclooxygenase-2 in Human Breast CancerJNCI Journal of the National Cancer Institute, 1998
- Replacement of Fhit in cancer cells suppresses tumorigenicityProceedings of the National Academy of Sciences of the United States of America, 1997
- Cyclooxygenase-2 gene expression in human breast cancerInternational Journal of Oncology, 1997
- The FHIT Gene, Spanning the Chromosome 3p14.2 Fragile Site and Renal Carcinoma–Associated t(3;8) Breakpoint, Is Abnormal in Digestive Tract CancersCell, 1996
- Fhit, a Putative Tumor Suppressor in Humans, Is a Dinucleoside 5‘,5‘ ‘‘-P1,P3-Triphosphate HydrolaseBiochemistry, 1996
- Homozygous deletion, rearrangement and hypermethylation implicate chromosome region 3p14.3‐3p21.3 in sporadic breast‐cancer developmentInternational Journal of Cancer, 1994